Clinical Trials (CTE)
NCCS is at the forefront of cancer clinical research in Singapore that is aimed at developing novel and up-to-date treatments to improve the lives of patients with different cancer types, including breast, lung, nasopharyngeal, stomach, colorectal and liver cancers. We have over a decade of experience in conducting clinical trials and have completed a broad spectrum of more than a hundred clinical trials to date. Our portfolio encompasses phases I to III trials, with most studies evaluating the effectiveness of novel molecular targeted agents.
In the Division of Medical Oncology, our investigators have been actively designing the protocols for these clinical studies. They are working closely with Clinical Trials Epidemiological Sciences department (CTE), headed by Assco Prof Tan Eng Huat, in the conduct of these trials.
Experimental Cancer Therapeutics Unit (ECRxU)
The Experimental Cancer Treatment Unit (ECRxU) was set up in 2009. It is part of the Division of Medical Oncology and headed by Dr Daniel Tan, a senior consultant in the Division of Medical Oncology, National Cancer Centre Singapore.
The primary mission of ECRxU is to bring novel therapeutic options to the clinic while concomitantly advancing the understanding of cancer biology through the design of science-driven trials. Its focus is on providing a single point of engagement for the conduct of Phase 0/1/2 trials. Through this unique translational interface, ECRxU works closely with scientists in NCCS, Duke-NUS, GIS and others, in order to increase the value of Phase I trials beyond simple does-finding studies. The unit coordinates the aspects of modern drug development from target discovery and validation, xenograft drug screening, clinical pharmacology and biomarker correlative clinical trials. This includes the ability to do sequential tumour biopsies for biomarker development in certain trials. ECRxU’s core interests cover all solid tumours and lymphomas.
From conceptualisation to the execution of biomarker intense Phase I trials, ECRxU has successfully amassed more than SGD 5 million in competitive grants as well as completed more than 30 clinical trials. In 2014, 110 patients were enrolled into Phase I trials including first-in-human studies.
Selected publications from members of the Division of Medical Oncology
1. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth
Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, Radaelli E, Al-Haddawi M, Tan SY, Hermans E, Amant F, Yan H, Lakshmanan M, Koumar RC, Lim ST, Derheimer FA, Campbell RM, Bonday Z, Tergaonkar V, Shackleton M, Blattner C, Marine JC, Guccione E. J Clin Invest. 2016 Jan 4;126(1):68-84. doi: 10.1172/JCI82534. (IF: 13.261)
2. Antibody-drug conjugates in non-Hodgkin lymphoma. Lim ST. Lancet Oncol. 2015 Jun;16(6):607-8. doi: 10.1016/S1470-2045(15)70161-0. (IF: 24.725)
3. SETD2 Histone Modifier Loss in Aggressive Gastrointestinal Stromal Tumors
Huang KK, McPherson JR, Tay ST, Das K, Tan IB, Ng CC, Chia NY, Zhang SL, Myint SS, Hu L, Rajasegaran V, Huang D, Loh JL, Gan A, Sairi AN, Sam XX, Dominguez LT, Lee M, Soo KC, Ooi LL, Ong HS, Chung A, Chow PK, Wong WK, Selvarajan S, Ong CK, Lim KH, Nandi T, Rozen S, Teh BT, Quek R, Tan P.. Gut. 2015 Sep 3.[Epub ahead of print] (IF: 14.66)
4. Tumour vascular-disrupting agents in soft-tissue sarcoma. Quek R. Lancet Oncol. 2015 May;16(5):480-1. doi: 10.1016/S1470-2045(15)70139-7. Epub 2015 Apr 8. (IF: 24.69)
5. Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study.
Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan GK, Tan YP, Yong WS, Preetha M, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, Chan A (2015) Ann Oncol 26(7) : 1446-51 (IF: 7.04)
6. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer.
Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WK, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Neuro Oncol. nov162 (IF: 6.776)
7. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY (2015) Lancet Oncol 16(3) : 293-300 (IF: 24.725)
8. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
Gainor JF, Tan DS, De Pas T, Solomon B, Ahmad A, Lazzari C, De Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT (2015) Clin Cancer Res 21(12) : 2745-52 (IF: 8.722)
9. Germline Heterozygous Variants in SEC23B are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer
Yehia L, Niazi F, Ni Y, Ngeow J, Sankunny M, Liu ZG, Wei W, Mester JL, Keri RA, Zhang B, Eng C. Am J Hum Genet. 2015 Nov 5;97(5):661-76. (IF: 20.931)
10. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial.
Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. J Clin Oncol. 2015 Jan 10;33(2):172-9. (IF: 18.428)
These 10 papers are selected from the total of 61 publications generated in 2015-2016.